Acceleron Pharma Inc: XLRN: NASDAQ: Common Stock Price Change Change Percent Stock Price Last Traded . Acceleron (XLRN) delivered earnings and revenue surprises of 1.04% and -6.62%, respectively, for the quarter ended September 2021. Pharmaceutical and Medicine Manufacturing Chemical Manufacturing Manufacturing Printer Friendly View Address: 128 Sidney St Cambridge, MA, 02139-4239 United States See other locations Phone: Website: www.merck.com Employees (this site): Modelled Employees (all sites): Actual Revenue: Actual Sales Growth: Assets: Fiscal Year End: Merck's (NYSE:MRK) Balance Sheet Can Easily Handle Acquisitions like Acceleron Pharma (NASDAQ: XLRN) nasdaq.com - November 21 at 8:45 AM. Historical and current end-of-day data provided by FACTSET. Cookie Notice (). 3rd Party Ad. Of the 137 institutional investors that sold Acceleron Pharma stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Wellington Management Group LLP ($1.01M), FMR LLC ($0.92M), Artisan Partners Limited Partnership ($0.77M), BlackRock Inc. ($0.69M), Lord Abbett & CO. A popular way to gauge a stock's volatility is its "beta". Acceleron Pharma Inc. is a biopharmaceutical company. Keytruda accounts for 36% of revenue. NASDAQ 0.00%. Furthermore, you can find the "Troubleshooting Login Issues" section which can answer your unresolved problems and equip you with a lot of relevant information. End-of-day quote Nasdaq It develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. Get a full understanding of how Acceleron Pharma Inc is performing with stock quotes and prices, as well as real-time news and analysis. Sign-up to receive the latest news and ratings for Acceleron Pharma and its competitors with MarketBeat's FREE daily newsletter. Medicines Golden Age Is Dawning. Please log in to your account or sign up in order to add this asset to your watchlist. Acceleron Pharma Inc. Stock Price (Quote) NASDAQ: XLRN. There are currently no items in this Watchlist. Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com Website. Find Salaries . Acceleron Temptation: Will Shareholders Accept Mercks Offer. Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Given we have quite a good number of analyst forecasts, it might be well . The biopharmaceutical company can be reached via phone at (617) 649-9200, via email at investor@acceleronpharma.com, or via fax at 617-649-9988. 0.00: 0.0%: 178.75: 20:00:00: Open Price Low Price High Price Close Price Prev Close; While the catalyst behind this double-digit jump wasn't immediately apparent (the company didn't release any material news during the week), Bloomberg News reported late Friday afternoon that the. Intraday Data provided by FACTSET and subject to terms of use. View which stocks are hot on social media with MarketBeat's trending stocks report. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. Acceleron Pharma is funded by 11 investors. Receive a free world-class investing education from MarketBeat. MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks. Approximately 7.8000 people live in KILWORTH, New Zealand. Acceleron Pharma (NASDAQ:XLRN) has a market capitalization of $10.93 billion and generates $92.52 million in revenue each year. The Smart Score is a quantitative, data-driven rating system and does not include human intervention. Part of the []. Relief Therapeutics: le conseil d'administration intgre Michelle Lo.. EN DIRECT DES MARCHES : L'Oral, Nestl, Airbus, Soitec, Valneva, .. Acceleron Pharma : Jefferies Starts Acceleron Pharma at Hold With $180 .. Acceleron Pharma : Raymond James Downgrades Acceleron Pharma to Market .. Acceleron Pharma : Oppenheimer Suspends Rating for Acceleron Pharma, $1.. Chief Scientific Officer & Senior Vice President. LoginAsk is here to help you access Acceleron Pharmaceutical quickly and handle each specific case you encounter. However, the big drugmaker recently revealed that it . The company employs 312 workers across the globe. Also showing relative strength are biotechnology shares, [], Getting high quality analyst coverage of your company as a recently minted IPO is important for communicating the rationale and excitement around your story. Furthermore, you can find the "Troubleshooting Login Issues" section which can answer your unresolved problems and equip you . View real-time stock prices and stock quotes for a full financial overview. View the latest Acceleron Pharma Inc. (XLRN) stock price, news, historical charts, analyst ratings and financial information from WSJ. Visit a quote page and your recently viewed tickers will be displayed here. Real-time trade and investing ideas on Acceleron Pharma, Inc. XLRN from the largest community of traders and investors. Acceleron Pharma is registered under the ticker NASDAQ:XLRN . Acceleron Pharma Inc (NASDAQ:XLRN) is not the most popular stock in this group but hedge fund interest is still above average. Its therapeutic areas include pulmonary and hematology. Zymeworks is announcing today it has struck a deal with Summit, NJ-based [], In trading on Monday, insurance brokers shares were relative leaders, up on the day by about 0.8%. Cardiovascular med sotatercept passed a phase 3 test as an add-on treatment for patients with pulmonary arterial hypertension (PAH), improving patients' six-minute walk distance Binance confirms its backing out of deal to buy FTX assets, Biden wants to discuss Taiwan, Russia, trade with Chinas Xi at G-20 summit, Investors fear potential FTX bankruptcy spilling over to reeling crypto, stock markets, Hurricane Nicole gathers strength, forcing evacuations in Florida, Potential railroad strike delayed until early December to allow for more votes, talks, Some Republicans urge Trump to delay 2024 presidential launch after midterm disappointment, Here are the congressional seats that have flipped in the midterm elections, Rivian posts narrower quarterly loss than Wall Street feared, keeps production guidance intact, Binance CEO in internal memo: I had very little knowledge of the internal state of things at FTX, Acceleron Pharma double downgraded to market perform from strong buy at Raymond James, Merck to pay $180 per Acceleron share in cash, Merck to acquire Acceleron Pharma in deal with equity value of $11.5 bln, Merck Closes Biggest Biotech Deal of the Year, Some Acceleron Investors Want a Better Deal From Merck, Merck to Refile Notification of Acceleron Merger Deal, Extending Deadline for Shareholders. The information on this page reflects the last day Acceleron Pharma was actively traded. At Acceleron Pharma Inc., we promise to treat your data with respect and will not share your information with any third party. ET by Barron's Acceleron's stock gains 3.9% on acquisition report Acceleron Pharma (XLRN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. Shares of Acceleron Pharma ( XLRN), a mid-cap hematology and pulmonary drugmaker, rose by a healthy 16.2% this week. For the best MarketWatch.com experience, please update to a modern browser. Mercks Covid Antiviral Isnt Just a Quick Win. Company profile page for Acceleron Pharma Inc including stock price, company news, press releases, executives, board members, and contact information 30, 2020- Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that it has priced an underwritten public offering of 4,864,864 shares of common stock at a price to the public of $92.50 per share for gross proceeds of $450.0 . KENILWORTH, N.J. & CAMBRIDGE, Mass.-- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Acceleron Pharma Inc. (Nasdaq: XLRN), a publicly traded biopharmaceutical company, today announced that the companies have entered into a definitive agreement under . DOW 0.00%. This puts Habib Dable in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Merck confirms to acquire Acceleron in a deal valued at $11.5 billion, Merck Reportedly Close to Buying Acceleron Pharma, Merck nears deal for rare-disease-drug maker Acceleron, Acceleron Stock Is Taking Off on Reported Potential Takeover, Acceleron's stock gains 3.9% on acquisition report. MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. What is Habib Dable's approval rating as Acceleron Pharma's CEO? See what's happening in the market right now with MarketBeat's real-time news feed. XLRN | Complete Acceleron Pharma Inc. stock news by MarketWatch. But another important and often under-appreciated source of capital are the debt markets taking a loan []. How were Acceleron Pharma's earnings last quarter? Stock Futures Mixed As Oil Rally Boosts Dow, Treasury . It is focused on discovery, development and commercialization of therapeutics to treat serious and rare diseases. Have Watchlists? The stock moves up in the pre-market trading session. Acceleron's REBLOZYL (luspatercept-aamt) is the first and only erythroid maturation agent approved in the United States, Europe, Canada and Australia for the treatment of anemia in certain rare. Acceleron Pharma, Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts. Real-time analyst ratings, insider transactions, earnings data, and more. to jointly develop and market ACE-011 in which Celgene paid Acceleron $50 million up front and bought $5 million of Acceleron stock, and agreed to buy $7 million more in stock if Acceleron went public, and agreed to pay up to $510 million in . But understanding the relationship between a forecasted price target of a stock and its [], By Alex Konrad and TrueBridge Capital Partners The 2014 Midas List features the top 100 tech investors in venture capital, and this years List is a formidable group. S&P 500 0.00%. Working at Acceleron Pharma | Glassdoor .
Mac Vanilla Vs Bartender, Morton's Toe Benefits, Jalapeno Cilantro Dip, Unity Gaming Services, Bodyguardian Heart Monitor How It Works, Cook County Mugshots 2022, Skyrizi Mechanism Of Action, Demon Slayer Game Sun Breathing,